Ankylosing spondylitis in sub-Saharan Africa

被引:25
作者
Belachew, D. A. [1 ]
Sandu, N. [1 ]
Schaller, B. [1 ]
Guta, Z. [1 ]
机构
[1] Univ Addis Ababa, Fac Med, Dept Neurol, Addis Ababa, Ethiopia
关键词
DOUBLE-BLIND; SULFASALAZINE; PLACEBO; SPONDYLARTHROPATHIES; SPONDYLOARTHRITIS; METHOTREXATE; THERAPY; RISK;
D O I
10.1136/pgmj.2007.064717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ankylosing spondylitis (AS) represents a chronic inflammatory bone disease of the axial skeleton that manifests as chronic back pain and progressive stiffness of the spine. It characteristically affects young adults with a peak age of onset between 20-30 years. In contrast to Western Europe and North America, the disease is rare in Sub-Saharan Africa where the majority of the population is HLA-B27 negative. Even in some African populations where HLA-B27 is prevalent (for example, in Gambia and Senegal, where 3-6% of the general population has HLA-B27), the disease is also said to be rare. However, some other genetic markers may be involved in the causation of AS in the HLA-B27 negative population, and when it occurs in this subgroup of patients it has a similar manifestation with HLA-B27 negative white patients and these patients rarely develop anterior uveitis. The clinical presentation of the disease in Africa is generally milder; most affected individuals do not have a family history of AS, the patients are older at onset of the disease, and the majority of them lack extra-articular manifestations such as anterior uveitis compared with the situation in Western Europe and North America. In conclusion, AS in sub-Saharan Africa seems to represent a subgroup of the disease, which may open the window to a greater understanding of the pathophysiology of the condition.
引用
收藏
页码:353 / 357
页数:5
相关论文
共 42 条
[11]   ANKYLOSING-SPONDYLITIS IN AFRICAN BLACKS [J].
CHALMERS, IM .
ARTHRITIS AND RHEUMATISM, 1980, 23 (12) :1366-1370
[12]  
Chen JM, 2006, J RHEUMATOL, V33, P722
[13]  
Clegg DO, 1999, ARTHRITIS RHEUM, V42, P2325, DOI 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO
[14]  
2-C
[15]  
Dagfinrud H, 2005, J RHEUMATOL, V32, P1899
[16]   SULFASALAZINE IN THE TREATMENT OF SPONDYLARTHROPATHY - A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
DOUGADOS, M ;
VANDERLINDEN, S ;
LEIRISALOREPO, M ;
HUITFELDT, B ;
JUHLIN, R ;
VEYS, E ;
ZEIDLER, H ;
KVIEN, TK ;
OLIVIERI, I ;
DIJKMANS, B ;
BERTOUCH, J ;
BROOKS, P ;
EDMONDS, J ;
MAJOR, G ;
AMOR, B ;
CALIN, A .
ARTHRITIS AND RHEUMATISM, 1995, 38 (05) :618-627
[17]  
Freedman B.A., 2005, Current Opinion in Orthopaedics, V16, P169, DOI [10.1097/01.bco.0000161722.07761.ff, DOI 10.1097/01.BCO.0000161722.07761.FF]
[18]  
Gonzalez-Lopez L, 2004, J RHEUMATOL, V31, P1568
[19]   FACTORS RELATED TO CHANGE IN GLOBAL HEALTH AFTER GROUP PHYSICAL THERAPY IN ANKYLOSING-SPONDYLITIS [J].
HIDDING, A ;
VANDERLINDEN, S .
CLINICAL RHEUMATOLOGY, 1995, 14 (03) :347-351
[20]   Mechanisms of disease: infection and spondyloarthritis [J].
Inman, RD .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (03) :163-169